In vivo imaging of sterile microglial activation in rat brain after disrupting the blood-brain barrier with pulsed focused ultrasound: [18F]DPA-714 PET study.
Authors: Sinharay S, Tu TW, Kovacs ZI, Schreiber-Stainthorp W, Sundby M, Zhang X, Papadakis GZ, Reid WC, Frank JA, Hammoud DA
Magnetic resonance imaging (MRI)-guided pulsed focused ultrasound combined with the infusion of microbubbles (pFUS+MB) induces transient blood-brain barrier opening (BBBO) in targeted regions. pFUS+MB, through the facilitation of neurotherapeutics' delivery, has been advocated as an adjuvant treatment for neurodegenerative diseases and malignancies. Sterile neuroinflammation has been recently described following pFUS+MB BBBO. In this study, we used PET imaging with [18F]-DPA714, a biomarker of translocator protein (TSPO), to assess for neuroinflammatory changes following single and multiple pFUS+MB sessions. Three groups of Sprague-Dawley female rats received MRI-guided pFUS+MB (Optison™; 5-8 × 10<sup>7</sup> MB/rat) treatments to the left frontal cortex and right hippocampus. Group A rats were sonicated once. Group B rats were sonicated twice and group C rats were sonicated six times on weekly basis. Passive cavitation detection feedback (PCD) controlled the peak negative pressure during sonication. We performed T1-weighted scans immediately after sonication to assess efficiency of BBBO and T2*-weighted scans to evaluate for hypointense voxels. [18F]DPA-714 PET/CT scans were acquired after the BBB had closed, 24 h after sonication in group A and within an average of 10 days from the last sonication in groups B and C. Ratios of T1 enhancement, T2* values, and [18F]DPA-714 percent injected dose/cc (%ID/cc) values in the targeted areas to the contralateral brain were calculated. Histological assessment for microglial activation/astrocytosis was performed. In all groups, [18F]DPA-714 binding was increased at the sonicated compared to non-sonicated brain (%ID/cc ratios > 1). Immunohistopathology showed increased staining for microglial and astrocytic markers in the sonicated frontal cortex compared to contralateral brain and to a lesser extent in the sonicated hippocampus. Using MRI, we documented BBB disruption immediately after sonication with resolution of BBBO 24 h later. We found more T2* hypointense voxels with increasing number of sonications. In a longitudinal group of animals imaged after two and after six sonications, there was no cumulative increase of neuroinflammation on PET. Using [18F]DPA-714 PET, we documented in vivo neuroinflammatory changes in association with pFUS+MB. Our protocol (utilizing PCD feedback to minimize damage) resulted in neuroinflammation visualized 24 h post one sonication. Our findings were supported by immunohistochemistry showing microglial activation and astrocytosis. Experimental sonication parameters intended for BBB disruption should be evaluated for neuroinflammatory sequelae prior to implementation in clinical trials.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To use [18F]-DPA-714 PET to detect and compare neuroinflammatory changes following single versus multiple MRI-guided pulsed focused ultrasound plus microbubble (pFUS+MB) sessions, with confirmation by immunohistochemistry.
Animal model / Human subject
Sprague-Dawley rat, 8–10 weeks old, female
Disease model
Healthy
MRI or image guidance method
MRI-guided using axial turbo-spin echo T2-weighted images on a 3T MRI scanner (Achieva) with a surface coil to determine pFUS targeting coordinates
Targeted brain region(s)
Frontal Cortex And Hippocampus
Cargo name and characteristics
[18F]DPA-714 — fluorine-18 radiolabeled small-molecule TSPO ligand (PET radiotracer), IV bolus (mean dose ~35 MBq, mass dose ~1.46 nmol/kg); Gadopentetate dimeglumine (Gd-DTPA, Magnevist) — gadolinium-based small-molecule MRI contrast agent, IV (100 uL) for BBB assessment.
Route of administration
Intravenous (tail vein)
Outcomes and Safety
Summary of Outcomes
MRI-guided pulsed FUS with microbubbles using PCD feedback (Optison 100 μL, 5–8×10^7 MB/rat infused over 1 min with a 30 s delay, 100% oxygen, PCD-limited PNP/ultraharmonics) produced transient BBB opening and induced sterile neuroinflammation (increased [18F]DPA-714 PET binding and Iba1/GFAP staining) detectable 24 h after a single sonication; two- and six-weekly sonications similarly induced neuroinflammation and progressively more T2* hypointense voxels (microhemorrhagic/iron deposition) but showed no cumulative increase in PET-measured inflammation in the longitudinal subset.
Duration of biological effect
2 weeks
Safety-related matter
pFUS+MB induced sterile neuroinflammation (increased [18F]DPA-714 PET binding) and histological microglial activation and astrocytosis, and MRI showed increasing T2* hypointense voxels consistent with microhemorrhagic changes/hemosiderin deposition with repeated sonications. Blood–brain barrier disruption resolved within 24 h and a small longitudinal subset showed no PET-detectable cumulative increase in neuroinflammation, but the authors recommend careful evaluation of neuroinflammatory sequelae prior to clinical trials.
Brain Region
Ultrasound Parameters
Ultrasound instrument
FUS Instruments ultrasound system (manufacturer: FUS Instruments, Toronto, ON); transducer center frequency = 548 kHz; focal diameter = 0.8; active (aperture) diameter = 7.5 cm
FUS Frequency
548 kHz; ultraharmonic monitoring at 1.5 f0 (≈822 kHz) and 2.5 f0 (≈1.37 MHz)
FUS Pressure
0 MPa (baseline), starting peak negative pressure 0.144 MPa with incremental increases of 0.008 MPa per pulse
FUS Mode
pulsed
Pulse duration
10 ms
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: 7.5 cm
Treatment frequency
Both single and multiple sessions
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search